Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence

Katherine E. Gallagher PhD [1,2*] & Fredrick Odiwour BSc.[1*], Christian Bottomley PhD[2], John Ojal PhD[1], Aisha Adamu PhD[3], Esther Muthumbi PhD[1], Eunice W. Kagucia PhD[1], Laura L Hammitt MD[4], Sergio Massora PhD[5], Betuel Sigaúque[5], Alberto Chaúque MSc[5], Leocadia Vilanculos MD[5], Jennifer R. Verani MD[6], Maria da Gloria Carvalho PhD[6], Anne von Gottberg PhD[7,8], Jackie Kleynhans PhD[7,9], Shabir A. Madhi PhD[10], Courtney P. Olwagen PhD[10], Grant Mackenzie PhD[11], Rasheed Salaudeen MSc[11], Ryan Gierke[6], Miwako Kobayashi MD[6], Stephen Pelton MD[12], Inci Yildirim PhD[12-16], Stepy Thomas MSPH[17], Amy Tunali MPH[17], Monica Farley MD[17], Todd D. Swarthout PhD[18,19], Akuzike Kalizang'oma PhD[18,19], Robert S. Heyderman FMedSci[18,19], Neil French PhD[19,20], Yoon Choi PhD[21], Nick Andrews PhD[21], Shamez Ladhani MRCPCH[21], Elizabeth Miller DSc[2], J. Anthony G. Scott FRCP[1,2]

[1] Epidemiology & Demography Department, KEMRI-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya
[2] London School of Hygiene & Tropical Medicine (LSHTM), UK
[3] International Health and Tropical Medicine, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
[4] International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
[5] Centro de Investigaçao em Saúde de Manhiça (CISM), Mozambique
[6] National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
[7] National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
[8] Department of Clinical Microbiology and Infectious Diseases (CMID), School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
[9] School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
[10] South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
[11] The Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine
[12] Boston University School of Medicine and Public Health, USA
[13] Department of Pediatrics, Section of Infectious Diseases and Global Health; Yale University School of Medicine, New Haven, CT
[14] Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT
[15] Yale Institute for Global Health, Yale University, New Haven, CT
[16] Yale Center for Infection and Immunity, Yale University, New Haven, CT
[17] Georgia Emerging Infections Program, Emory University School of Medicine, USA
[18] Research Department of Infection, Division of Infection and Immunity, University College London
[19] Malawi-Liverpool-Wellcome Clinical Research Programme, Malawi
[20] Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool,
[21] UK Health Security Agency (UKHSA), London, England.

*these authors contributed equally to the analysis

Corresponding author: Katherine Gallagher, KEMRI Wellcome Trust Research Programme, PO Box 230, 80108, Kilifi, Kenya. Email: Katherine.gallagher@lshtm.ac.uk; tel: +254707867625

Keywords: pneumococcus, invasiveness, case-carrier ratio

Word count: 3500/ 3500

Abstract (295/300)

Background
Serotype-specific estimates of pneumococcal invasiveness used in pneumococcal carriage transmission models to predict changes in disease incidence post-vaccination are largely derived from high-income settings. We conducted a systematic review of carriage prevalence and invasive pneumococcal disease (IPD) incidence to calculate case-carrier ratios (CCRs) in different income settings.

Methods
A systematic search of Medline, Embase, and Global Health databases in March 2022 identified publications on pneumococcal carriage prevalence or IPD incidence; we requested individual-level data from authors of relevant texts. Serotype-specific CCRs, calculated as IPD incidence divided by carriage prevalence, were pooled across settings using random effects meta-analyses, stratified by pre-/post-pneumococcal conjugate vaccine (PCV) introduction, country income group, age-group, sex and HIV status.

Findings
We identified 80 publications from 18 countries (13 upper-middle- or high-income countries (UM/HIC), 5 low/lower-middle income (L/LMIC)) reporting carriage prevalence or IPD incidence in overlapping geographical areas, time periods, and age-groups. We calculated CCRs for >70 serotypes, stratified by age group, income settings, and pre- and post-vaccine introduction. In children under five, pre-PCV CCRs for serotypes not included in the 20-valent PCV were higher in L/LMICs than UM/HICs, 152 (95% Confidence interval 103-226) versus 102 (50-209). Post-PCV CCRs for non-vaccine serotypes dropped in UM/HICs but not in L/LMICs, 19 (16-22) versus 154 (119-200) respectively. Pre-/post PCV changes varied by serotype and age-group. CCRs were lowest in 5–14-year-olds and were higher in HIV positive than HIV negative individuals. There were no differences in CCRs by sex.

Interpretation
Pneumococcal invasiveness varies by serotype, age-group, country income-group, HIV status and over time; however, substantial variation remained unexplained. Our CCRs represent the most representative estimates of invasiveness currently available for use in statistical or mathematical prediction models of disease incidence, where only carriage prevalence data are available.

Funding: The Wellcome Trust, Great Britain (098532)

Panel: Research in context

Evidence before this study

There are three estimates of the absolute risk of invasive pneumococcal disease, given carriage, derived from data from high-income settings (two studies in the UK, and one in the USA). A fourth set of estimates have been derived from data collated by a recent review of studies that reported both carriage and IPD data in the same publication. This review and re-analysis combined data from 12 countries to report case-carrier ratios in children under-5, pre- and post-vaccine introduction. The review did not include data from IPD surveillance sites in low- and middle-income countries, nor carriage prevalence data in adults.

Added value of this study

We conducted an extensive systematic review to identify high quality IPD incidence estimates and a comprehensive database of carriage prevalence estimates that arise from the same country, age-group and time period as these IPD incidence estimates. We employed stringent matching criteria to only include the results of carriage surveys that were conducted in a random sample of the general population, and IPD surveillance activities that were conducted in a systematic way across a defined population. This enabled us to estimate serotype-specific pneumococcal case-carrier ratios, stratified by age group, country income group, and time period pre- or post-vaccine introduction.

Implications of all the available evidence

Invasive pneumococcal disease surveillance is resource intensive to establish and sustain and is therefore infeasible for most countries worldwide. Pneumococcal vaccine policy is often made on the basis of carriage data alone, or mathematical models which predict changes in disease incidence by combining changes in carriage prevalence with pre-specified case-carrier ratios. We have used all available data globally to estimate serotype-specific case-carrier ratios, which previously have been derived from data from high income settings. Both statistical and mathematical models predicting changes in disease incidence in low-income settings, can now utilise case-carrier ratios from more relevant population groups. This will be of increasing importance as policy makers attempt to make evidence-based decisions on whether to change pneumococcal vaccine product, schedule, or simply increase coverage of the existing programme.

Introduction

Streptococcus pneumoniae (pneumococcus) causes respiratory tract infections, sepsis, and meningitis. In 2021, pneumococci are estimated to have caused 98 million episodes of lower respiratory tract infection (uncertainty interval, UI, 92–104) and 505 000 deaths (UI 454 000– 555 000) worldwide(1). Together with bacteraemia and meningitis, this equates to 493 disability-adjusted life years (DALYs) lost per 100,000 population across all ages (UI 408-602)(2).

Carriage of pneumococci is a necessary precursor to disease(3). Pneumococcal conjugate vaccines (PCVs) have been highly effective at preventing carriage and disease caused by the pneumococcal serotypes included in the vaccine ('vaccine types', VTs), but the vaccines are expensive(4). New PCVs which expand protection of the current 10 and 13-valent products, to 15 or 20 serotypes, have been recently licensed for paediatric use by the European Medicines Agency and other higher valency products are in development. Evidence of PCV impact on disease is essential to justify the PCV programme's ongoing expense and predict the impact of future changes in vaccine schedule or product(5).

PCV impact studies would ideally use invasive pneumococcal disease (IPD) surveillance as the primary outcome(6); however, IPD surveillance is resource intensive to establish and maintain over the long periods of time needed to measure changes in incidence, and to then attribute these changes to a particular vaccine policy(7). Carriage surveys are easier and less costly to conduct, but the outputs then need to be translated into a clinically relevant outcome, like IPD. Accurate measures of serotype-specific pneumococcal invasiveness could be used in statistical models to convert carriage prevalence estimates from carriage surveys into an estimate of disease burden in areas where IPD surveillance is too costly to implement(8, 9). Mathematical models of the impact of new PCVs already use estimates of invasiveness (case-carrier ratios [CCRs]) to predict the impact of the replacement in carriage of vaccine types with non-vaccine types on disease burden(10).

Prior estimates of invasiveness have demonstrated that invasiveness varies significantly by serotype(11, 12). In high-income settings, the absolute risk of invasion, given carriage, has been estimated using data on carriage prevalence and IPD incidence (13-15). A recent review(16) re-analysed data from studies that reported both carriage prevalence and IPD incidence in order to calculate CCR, but did not include data from IPD surveillance sites in low and middle income countries, nor carriage prevalence data from adults(17-19). We aimed to estimate serotype-specific pneumococcal CCRs by collating all available data on carriage prevalence and IPD incidence globally, and to determine if invasiveness varies by age, sex, HIV status, country income group, and pre- or post-PCV introduction, to inform the use of CCRs in estimating IPD burden.

Methods

Search Strategy and selection criteria

We conducted systematic searches of Medline, Embase (Ovid SP), and Global Heath databases, for publications and conference abstracts using search terms for pneumococcus, and carriage or invasive disease (**Supplementary Figure 1**). Searches were performed on 14th March 2022 with no geographical, age, or year restrictions. Titles and abstracts were screened by two authors. Titles and abstracts that reported any pneumococcal carriage or disease incidence data, or both, were included if an abstract was available in English. Full texts were retrieved, screened by two authors, and included in a long-list if they reported the serotype-specific results of either representative surveys

172 of carriage prevalence among healthy people, or IPD surveillance activities in a defined population
173 (**Figure 1**). Discrepancies in selection were resolved by a third author.
174
To further refine the selection, one author extracted basic study characteristics from all full texts i.e.,
the outcome reported, calendar year(s), country(ies) and age-groups included in data collection. A
process of matching reports of carriage prevalence and IPD incidence was then undertaken.
Publications of carriage prevalence were included if they overlapped by at least one calendar year
with data available on IPD incidence from the same country. In addition, both carriage and IPD data
had to have been collected in the same PCV period (either pre-PCV or post-PCV). Publications on IPD
and carriage in the same country and calendar period had to have sampled within the same age
group (i.e., aged under-5-years (data reported in children less than 6 or 7-years were also included),
5-14 year olds (data reported in 5-17 or 5-18 year olds were also included in this group), and 15
years and above (data reported in 18 year olds and above were also included in this group)).
Additionally, if both carriage and IPD data were from children aged under-5-years, both estimates of
carriage and IPD had to either include or exclude infants (aged <12 months). If estimates of carriage
and IPD were both in 15-year-olds and above, both estimates had to either include or exclude those
aged >65-years. This is because data from infants and >65s dominate IPD incidence estimates.
189
190 <u>Data extraction</u>
191
Investigators were approached to provide individual level data on IPD cases, population
denominators and carriage survey participants, including, where available, age, sex, PCV, and HIV
status. Data were shared by investigators from Kenya, Malawi, Mozambique, South Africa, The
Gambia, United States of America and England and Wales. If individual level data could not be
obtained (an additional 11 countries), data were extracted from publications. The country's World
Bank income group was based on the classifications available in 2022. PCV introduction status at the
time of sampling was defined using data from VIEW-hub(20).
199
200 <u>Statistical analysis</u>
201
202 For each serotype-specific 'match' of IPD incidence data to carriage prevalence data, a case-carrier
203 ratio (CCR) and an estimate of its variance was calculated using formula:
204

$$CCR = \lambda/p$$

205
206 where λ is the incidence of IPD, calculated as the number of cases of IPD per 100,000 person-years,
207 and p is the carriage prevalence. A 95% confidence interval for each CCR was obtained via the delta
208 method(21) (**Supplementary Figure 2**).
209
Where there was an estimate of carriage prevalence for a specific serotype, age and year group, but
there were zero reported cases of disease, or, where there were reported cases of disease but zero
detected carriers, a case-carrier ratio could not be computed. To avoid underestimating the
invasiveness of highly invasive but rarely carried serotypes (e.g., serotypes 1 and 5) and
overestimating the invasiveness of frequently carried but less invasive serotypes, we replaced zero
incidence and prevalence estimates with imputed small, non-zero values. Imputation used an
empirical Bayes approach. We fitted serotype-specific beta binomial models to the observed counts,
with age-group, country income group and PCV introduction status as covariates(22). The beta
distribution estimated from this model was used as a prior and combined with the observed zero
count to derive a posterior distribution. The mean of this posterior, μ_{post}, was used to generate a
small non-zero imputed value:
221

$$\mu_{post} = \frac{\mu_{prior}}{1 + \sigma_{prior} n}$$

222
223
224 where μ_{prior} and σ_{prior} are, respectively, the mean and overdispersion parameter of the beta prior
225 (estimated by fitting the beta-binomial model) and n is the sample size (carriage prevalence) or
226 person years (IPD incidence) of the study. Note that the imputed value, μ_{post}, is close to the μ_{prior}
227 when n is close to zero and close to zero when n is large. The resultant imputed values were only
228 used if observed counts were zero.
229
230 To combine serotype-specific CCRs across studies and groups, summary estimates were produced
231 using serotype-specific random effects meta-analyses, allowing for estimates to vary between
232 studies(23). Summary estimates were stratified by age, country income group, and calendar year or
233 period (pre- or post-PCV) and were made available for download via a Shiny app
234 (https://pneumovaxpol.shinyapps.io/Pneumo_CCR_MetaAnalysis/).
235
In internal calibration, reported serotype-specific carriage prevalences post-PCV introduction were
multiplied by the serotype-specific CCR estimate obtained by pooling data from all the countries in
the same income group to calculate the predicted IPD incidence in under-5s. This was compared
with observed IPD incidence. Exploratory analyses of the variation in invasiveness across countries
used country level data extracted from the UNAID and WHO Global Health Observatory databases,
including HIV prevalence in adults aged 15-49 years, the prevalence of underweight children, the
proportion of children with pneumonia who are taken to a health facility, the prevalence of
handwashing facilities and cooking with biomass at home, and third dose PCV coverage among
infants. A mixed linear effects model was built to assess the association of these country-level
factors with CCRs, controlling for clustering by serotype.
246
The individual level data obtained from authors were split into datasets corresponding to sex (male
or female) and HIV status (infected or uninfected). The sizes of the surveillance populations were re-
estimated for each specific sub-group of the population using the most recent age-specific census
estimates on the ratio of men to women, and population level data on HIV prevalence by age group
and calendar year using the Thembisa model(24). Since the percentage of IPD cases missing HIV
status was high (55% - 68%; **Supplementary Table 1**), we imputed the HIV status of cases with
missing data. We performed multiple imputation using chained equations and generated 20 imputed
datasets(25, 26). The imputation was based on a logit model using information on sex, age group,
IPD status, and carriage. The estimates from the imputed datasets were then combined using
Rubin's rule. We conducted three analyses: 1) an analysis excluding records with missing data, 2) an
analysis using imputed values, 3) a sensitivity analysis assigning all cases with missing HIV status to
HIV-uninfected. CCRs were recalculated for each record in the dataset and combined using random
effects meta-analyses, stratified by sex and HIV status.
260
261 The project received ethical approval from London School of Hygiene & Tropical Medicine (Ref:
262 27394). This activity was reviewed by CDC, deemed not research, and was conducted consistent with
263 applicable federal law and CDC policy (e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42
264 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.) The funder of the study had no role
265 in study design, data collection, data analysis, data interpretation, or writing of the report.
266
267
268 **Results**
269
270 <u>Included studies</u>

271
A total of 4922 titles and abstracts were screened, and 1165 full texts were assessed for eligibility;
732 publications reported either pneumococcal carriage prevalence or IPD incidence in defined
populations. A total of 80 publications from 18 countries reported data on carriage prevalence and
IPD incidence in populations in the same country, in overlapping calendar years and age groups and
therefore contributed to the analysis (**Figure 1**). For the group level analyses by age-group, country,
and time, data from 57,962 participants in carriage surveys and 41,238 IPD cases were included
(**Table 1**; **Supplementary Table 2**). Of note, the only upper-middle/high-income countries (UM/HICs)
contributing data in adults were England and Wales, and South Africa. We excluded data from South
Africa from the UM/HIC grouping at all ages because of the significant differences in CCRs when
stratified by HIV status and the heterogeneity introduced when South African CCRs were combined
with other UM/HICs.
283
284 For the individual level analyses by sex and HIV status, we received individual-level data on the sex
285 of IPD cases and carriage survey participants from six countries: The Gambia, Kenya, Malawi,
286 Mozambique, England and Wales, and South Africa. Only the South African dataset included the HIV
287 status for both IPD cases and carriage survey participants (**Supplementary Table 1**).
288
289 <u>Population level analysis comparing pre- and post-PCV periods</u>
290
In under-5s, when grouping serotypes into vaccine-types and non-vaccine types (NVTs, i.e., non-
PCV20 types), the CCR for PCV7-types declined after PCV introduction (**Table 2**). In under-5s, CCRs
for NVTs declined after PCV introduction in UM/HIC from 102 (95%CI 50-209) to 19 (16-22) post-PCV
introduction; but not in low/lower-middle income countries (L/LMICs) where NVT CCRs were 152
(95%CI 103-226) pre-PCV and 154 (119-200) post-PCV (**Table 2**). Differences in CCRs pre- vs. post-
PCV introduction were only significant for some serotypes. For example, in under-5s in L/LMICs,
ST14 was significantly less invasive post-PCV compared with pre-PCV; in UM/HICs, ST9V, 18C & 35B
were less invasive post-PCV compared with pre-PCV. In populations over 15 years of age, in L/LMICs
VT and NVT CCRs decreased post-PCV introduction; in England and Wales, CCRs for NVTs increased
post-vaccine introduction and in serotype specific analyses ST3 was significantly more invasive post-
PCV introduction (and post-PPV23 introduction in adults), compared to the pre-vaccine period
(**Supplementary Figure 3**).
303
304 <u>Population level analysis comparing L/LMIC and UM/HIC data</u>
305
306 In under-5s, in both pre- and post-PCV periods, CCRs tended to be higher in L/LMIC compared to
307 UM/HIC. Post-PCV introduction in under-5s, CCRs were significantly higher in L/LMICs than in
308 UM/HICs for serotypes 1, 10A, 12F, 15A, 15B, 16F, 35B, 7C and 9N. In populations over 15 years of
309 age, CCRs tended to be higher in UM/HICs compared to L/LMICs, significantly so for serotypes 3, 19A
310 and 8 (**Figure 2**).
311
312 <u>Population level analysis by age-group</u>
313
In both pre- and post-PCV periods, CCRs were higher in under-5s and over 15 years-of-age, and
lower in 5-14 year olds (**Table 2**; serotype-specific CCRs are available:
https://pneumovaxpol.shinyapps.io/Pneumo_CCR_MetaAnalysis/). The 5 additional types included
in PCV20 but not in PCV15, are highly invasive in under-5s in L/LMICs and in adults in UM/HICs. In
adults in UM/HICs, among a population of carriers of the PCV20 additional serotypes, the expected
incidence of IPD would be >200 per 100,000 person years (**Table 2**).
320
321 <u>Population-level trends over time</u>

322
Where we had data by calendar year prior to and/or following PCV introduction, we analysed
whether there were trends over time relative to PCV introduction, restricted to the under-5 age-
group. We fitted a linear mixed model to the natural log of the CCRs over years relative to PCV
introduction (from -8 to +10 years), controlling clustering by country and serotype. There was
significant variation in CCRs over time, but no clear trends in L/LMICs or UM/HICs. There was a
downward trend in invasiveness in South African CCRs over time since PCV introduction
(**Supplementary Figure 4**).
330
331 <u>Internal calibration</u>
332
In internal calibration using data from under-5s, the predicted IPD burden was similar to the
observed IPD burden for The Gambia, Mozambique and the USA, but was different for Kenya,
Malawi and the UK (**Supplementary Table 3**). Pooled CCRs were weighted to represent datasets
which contributed the most IPD cases, and the largest carriage surveys. In an exploratory linear
mixed effects model of CCRs from L/LMICs in under-5s, post-PCV, countries with higher care seeking
for pneumonia and with a higher proportion of households with handwashing facilities correlated
with lower CCRs. Countries with higher prevalences of underweight under-5s were correlated with
higher CCRs. The prevalence of HIV in adults, third dose PCV coverage, and the prevalence of
biomass fuel use in homes did not correlate with differences in CCRs (**Supplementary Table 4**).
342
343 <u>Individual level analysis by sex and HIV status</u>
344
There were no significant differences in CCRs by sex; the comparison groups of males and females
included a balanced distribution of data from the pre- and post-PCV era (**Supplementary Figure 5**).
In South Africa, there were large differences in invasiveness by HIV status across the data pre and
post-PCV; all serotypes were more invasive in HIV-infected compared to HIV-uninfected people in
the same age stratum (**Figure 3).** The differences in CCRs between HIV-infected and HIV-uninfected
groups increased when imputed data on HIV status of IPD cases was used (**Supplementary Figure 6**).
Between 2009-2018, the proportion of invasive pneumococcal disease attributable to HIV infection
in South Africa was 33.6% (95%CI 30.6-36.6) in children under-5 years of age, 63.8% (95%CI 59.7-
67.9) in children 5-14 years, and 76.1% (95%CI 74.8-77.5) in those 15 years and above; however
there are likely to be decreasing trends over time (**Supplementary Table 5**).
355
356 **Discussion**
357
We aggregated global data from carriage surveys and IPD surveillance. The strength of this review
and analysis is its global reach, we have included data from over 40,000 isolates of IPD and over
50,000 carriage survey participants, from a diverse range of settings. We have built on estimates
from a prior review(16), which did not disaggregate data by PCV period, and included predominantly
high-income country data on children (**Supplementary Table 6**). Our analysis enabled further
stratification to refine estimates by country income group, age group and period relative to PCV
introduction. We have shown significant differences in invasiveness by serotype, age, population,
time period, and no differences by sex. Future statistical or mathematical prediction models of IPD
incidence can now use the most relevant of the pooled CCRs for the setting and population of
interest.
368
Among under-5s, the decrease in invasiveness post-PCV introduction for vaccine serotypes is
expected as the vaccine confers direct protection against invasion that is independent from the
protection from carriage acquisition (27-29). However, there are some surprising differences post-
PCV introduction in adults, including a decrease in both NVT and VT CCRs among PCV-unvaccinated

adults in L/LMIC. These observations could be explained by reductions in host susceptibility over
time and/or that the sensitivity of NVT detection in carriage and diversity of circulating NVTs has
increased since PCV introduction, when the dominant vaccine types have been removed(15, 30).
This would have overestimated CCRs for NVTs in the pre-vaccine era. In UM/HIC it is notable that we
only were able to obtain data on adults from England & Wales and South Africa. This is a significant
gap in the literature given the high burden of IPD in adults and the development of vaccines tailored
to the prevention of adult IPD (e.g., PCV21)(31).
380
We estimated that pneumococci are more invasive in L/LMICs, compared to UM/HICs. However,
there was substantial variation in CCRs by country. Many factors are likely to influence host
susceptibility, including coinfections, malnutrition, air quality, epithelial integrity, and living
conditions(32). The comparison of CCRs in L/LMICs and UM/HICs could also be confounded if IPD
incidence is, in fact, driven by rates of carriage acquisition, rather than prevalence, and the
relationship between carriage prevalence and rates of acquisition differs in L/LMIC compared to
UM/HIC (e.g.,with different durations of carriage)(33-36).
388
In South Africa, serotype-specific CCRs ranged from 2 to 200 times higher in HIV-infected, compared
to HIV-uninfected people. Before anti-retroviral therapy (ART) became available, people infected
with HIV had 43 times higher incidence rates of IPD than HIV-uninfected populations(37). However,
we also showed CCRs in South Africa have been declining over time, which could be explained by the
expansion of access to ART, improved diagnostics and prevention of mother to child transmission,
and therefore changing levels of immunosuppression among HIV infected populations over time(38,
39). Our comparison of CCRs among HIV-infected and HIV-uninfected did not account for this secular
trend as we used all available data from 2010-18.
397
A limitation of our analysis is the combination of carriage and IPD data from different areas of the
same country and different time periods; we attempted to limit the amount of heterogeneity this
introduced with our matching criteria. We had to assume that cross sectional carriage prevalence is
representative of the population carriage prevalence across an entire year in order to calculate CCRs;
however, seasonal variation in carriage has been documented and seasonal variation in invasiveness
is likely given that variation in IPD incidence over the course of a year is greater than the variation
observed in carriage prevalence(40). In internal validation, pooled CCRs more closely represented
datasets which contributed the most IPD cases, which meant they overestimated IPD burden in
settings in the same income group, with lower observed IPD incidence (**Supplementary Table 3**).
There is substantial variation in invasiveness and IPD burden across different settings that cannot be
explained by carriage prevalence and pooled CCRs alone, despite matching data as rigorously as
possible, and stratifying the analysis on time period, geography and age group. IPD surveillance
sensitivity, including health seeking behaviour, case ascertainment at the facility, sample collection
and the rate of laboratory detection of pneumococci, varies across different settings. In children, we
may have underestimated the difference in CCRs between L/LMIC and UM/HIC, as IPD surveillance is
likely to be of lower sensitivity in L/LMICs. In adults, the reportedly higher CCRs in UM/HIC may be
due to low sensitivity of IPD surveillance among adults in L/LMICs, as well as the difference in the
age-distribution of the populations (UM/HICs have older adult populations). All the comparisons of
pooled CCRs over time and across different settings are confounded by the fact that comparison
groups contain different proportions of data from different countries.
418
Additionally, pneumococci were isolated and serotyped in different ways across the included studies
(e.g., by culture and Quellung, latex agglutination and/or mPCR). There were not enough studies
using mPCR to compare how the sensitivity of this method of detection/ multiple serotype carriage
may have influenced CCRs. Our CCRs are only representative of studies which detected a single
serotype. We did not have genomic data on pneumococcal strains; there will be residual

confounding in our comparisons of invasiveness across different time periods and countries as it is
likely that some of the variability is due to differences in circulating strains of the same serotype(16).
However, although sequencing has indicated that strains of serotype 35B in the United States have
acquired virulence genes over time(41), in our analysis we do not see an increase in overall
invasiveness because carriage prevalence has also increased over time. All the studies included used
cross-sectional carriage surveys to estimate carriage prevalence; this will underestimate the
prevalence of serotypes with short durations of carriage. To attempt to account for this we imputed
very small values of prevalence among studies which reported 'zero' prevalence of rarely carried but
invasive types.
433
Conclusion
435
High quality IPD surveillance is resource intensive and infeasible for most countries worldwide. We
have calculated serotype-specific estimates of pneumococcal invasiveness (available:
https://pneumovaxpol.shinyapps.io/Pneumo_CCR_MetaAnalysis/) and have demonstrated
invasiveness varies across different populations, age-groups and over time. The most relevant of
these pooled estimates could be used in statistical or mathematical models to extrapolate from
carriage prevalence data to predict changes in disease incidence where only carriage prevalence is
known. This would inform PCV policy decisions including, for example, strategies to increase vaccine
coverage, change schedule or introduce a new product.
444
Author contributions

Katherine E. Gallagher: accessed data for the formal analysis, project administration, visualization,

writing original draft, final responsibility for the decision to submit the manuscript for publication

Fredrick Odiwour: accessed data for the formal analysis, writing, review & editing

Aisha Adamu, Esther Muthumbi, Eunice W. Kagucia, Laura L Hammitt, Sergio Massora, Betuel

Sigaúque, Alberto Chaúque, Leocadia Vilanculos, Jennifer R. Verani, Maria da Gloria Carvalho, Anne

von Gottberg, Jackie Kleynhans, Shabir A. Madhi, Courtney P. Olwagen, Grant Mackenzie, Rasheed

Salaudeen, Ryan Gierke, Miwako Kobayashi, Stephen Pelton, Inci Yildirim, Stepy Thomas, Amy Tunali,

Monica Farley, Todd D. Swarthout, Akuzike Kalizang'oma, Robert S. Heyderman, Neil French, Yoon

Choi, Nick Andrews, Shamez Ladhani, Elizabeth Miller: data curation, review & editing

C. Bottomley: supervision, review & editing

JAG Scott: conceptualization, funding acquisition, supervision, review & editing

457
Declaration of interests

459 None

Data Sharing

462 Pooled estimates resulting from the meta-analyses conducted in this paper are available for

463 download via a ShinyApp together with relevant meta-data. Individual level data received from

464 authors for the purposes of this review and metaanalyses, are available from the original

465 investigators only, under applicable data sharing agreements.

Acknowledgements

Staff time spent conducting the review and meta-analyses was funded by the Wellcome Trust

(098532). The funding sources had no role in the study design; collection, analysis and interpretation

of data; and in the decision to submit for publication.

We thank the authors of the original research collated here which enabled us to conduct this

analysis.

This paper is published with the permission of the Director, Kenya Medical Research Institute. The

findings and conclusions in this report are those of the author(s) and do not necessarily represent

the official position of the Centers for Disease Control and Prevention.

References

1.   Bender RG, Sirota SB, Swetschinski LR, Dominguez R-MV, Novotney A, Wool EE, et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet Infectious Diseases. 2024;24(9):974-1002.

2.   Naghavi M, Mestrovic T, Gray A, Gershberg Hayoon A, Swetschinski LR, Robles Aguilar G, et al. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Infectious Diseases. 2024;24(8):868-95.

3.   Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nature Reviews Microbiology. 2018;16(6):355-67.

4.   Ojal J, Griffiths U, Hammitt LL, Adetifa I, Akech D, Tabu C, et al. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya. The Lancet Global Health. 2019;7(5):e644-e54.

5.   Rodgers GL, Klugman KP. Surveillance of the impact of pneumococcal conjugate vaccines in developing countries. Human vaccines & immunotherapeutics. 2016;12(2):417-20.

6.   Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, et al. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms. 2021;9(4):742.

7.   World Health Organization. Pneumococcal vaccines WHO position paper--2019. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. 2019;8(94):85-104.

8.   Weinberger DM, Bruden DT, Grant LR, Lipsitch M, O'Brien KL, Pelton SI, et al. Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in Invasive Disease. American Journal of Epidemiology. 2013;178(9):1488-95.

9.   Adamu AL, Ojal J, Abubakar IA, Odeyemi KA, Bello MM, Okoromah CAN, et al. The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria. Nature communications. 2023;14(1):2666.

10.   Choi YH, Andrews N, Miller E. Estimated impact of revising the 13-valent
pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A
modelling study. PLoS medicine. 2019;16(7):e1002845.
11.   Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal
and geographic stability of the serogroup-specific invasive disease potential of
Streptococcus pneumoniae in children. Journal of Infectious Diseases. 2004;190(7):1203-11.
12.   Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Muñoz-Almagro C, et al. The
relative invasive disease potential of Streptococcus pneumoniae among children after PCV
introduction: A systematic review and meta-analysis. J Infect. 2018;77(5):368-78.
13.   Flasche S, Hoek AJV, Sheasby E, Waight P, Andrews N, George R. Effect of
pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in
England: a cross-sectional study. PLoS medicine. 2011;8.
14.   Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, et al.
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal
disease. Vaccine. 2010;29(2):283-8.
15.   Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, et al.
Pneumococcal carriage in children and their household contacts six years after introduction
of the 13-valent pneumococcal conjugate vaccine in England. PloS one.
2018;13(5):e0195799.
16.   Løchen A, Truscott JE, Croucher NJ. Analysing pneumococcal invasiveness using
Bayesian models of pathogen progression rates. PLOS Computational Biology.
2022;18(2):e1009389.
17.   Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S. Population
effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of
Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya:
findings from cross-sectional carriage studies. Lancet Glob Heal. 2014;2.
18.   Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, et al. High
residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of
pneumococcal conjugate vaccine in Malawi. Nature communications. 2020;11(1):2222.
19.   Valenciano SJ, Moiane B, Lessa FC, Chaúque A, Massora S, Pimenta FC, et al. Effect of
10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal
Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal
Conjugate Vaccine Introduction in Mozambique. Journal of the Pediatric Infectious Diseases
Society. 2021;10(4):448-56.
20.   International Vaccine Access Center (IVAC). VIEW-hub Report: Global Vaccine
Introduction and Implementation. . Johns Hopkins Bloomberg School of Public Health; 2022.
21.   Oehlert GW. A Note on the Delta Method. The American Statistician. 1992;46(1):27-
9.
22.   Hardin JW, Hilbe JM. Estimation and Testing of Binomial and Beta-Binomial
Regression Models with and without Zero Inflation. The Stata Journal. 2014;14(2):292-303.
23.   Dettori JR, Norvell DC, Chapman JR. Fixed-Effect vs Random-Effects Models for Meta-
Analysis: 3 Points to Consider. Global Spine J. 2022;12(7):1624-6.
24.   Johnson LF, Meyer-Rath G, Dorrington RE, Puren A, Seathlodi T, Zuma K, et al. The
Effect of HIV Programs in South Africa on National HIV Incidence Trends, 2000-2019. Journal
of acquired immune deficiency syndromes (1999). 2022;90(2):115-23.
25.   Schafer JL. Multiple imputation: a primer. Statistical methods in medical research.
1999;8(1):3-15.

26. Lee JH, Huber Jr J, editors. Multiple imputation with large proportions of missing
data: How much is too much? United Kingdom stata users' group meetings 2011; 2011:
Stata Users Group.
27. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal
conjugate vaccine: evidence from Northern California. Eur J Pediatr. 2002;161 Suppl 2:S127-
31.
28. Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A. Immunogenicity,
impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable
Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1–4 years: a
randomized controlled trial. PloS one. 2014;9.
29. Temple B, Tran HP, Dai VTT, Smith-Vaughan H, Licciardi PV, Satzke C, et al. Efficacy
against pneumococcal carriage and the immunogenicity of reduced-dose (0⊠+⊠1 and 1⊠+⊠1)
PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind,
randomised controlled trial. The Lancet Infectious diseases. 2023;23(8):933-44.
30. Olwagen CP, Adrian PV, Madhi SA. Comparison of traditional culture and molecular
qPCR for detection of simultaneous carriage of multiple pneumococcal serotypes in African
children. Scientific reports. 2017;7(1):4628-.
31. Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al.
Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of
the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb
Mortal Wkly Rep. 2024;73(36):793-8.
32. Glennie SJ, Williams NA, Heyderman RS. Mucosal immunity in resource-limited
setting: is the battle ground different? Trends Microbiol. 2010;18(11):487-93.
33. Dube FS, Ramjith J, Gardner-Lubbe S, Nduru P, Robberts FJL, Wolter N, et al.
Longitudinal characterization of nasopharyngeal colonization with Streptococcus
pneumoniae in a South African birth cohort post 13-valent pneumococcal conjugate vaccine
implementation. Scientific reports. 2018;8(1):12497.
34. Murad C, Dunne EM, Sudigdoadi S, Fadlyana E, Tarigan R, Pell CL, et al.
Pneumococcal carriage, density, and co-colonization dynamics: a longitudinal study in
Indonesian infants. International journal of infectious diseases : IJID : official publication of
the International Society for Infectious Diseases. 2019.
35. Chaguza C, Senghore M, Bojang E, Lo SW, Ebruke C, Gladstone RA, et al. Carriage
Dynamics of Pneumococcal Serotypes in Naturally Colonized Infants in a Rural African
Setting During the First Year of Life. Front Pediatr. 2020;8:587730.
36. Metcalf BJ, Waldetoft KW, Beall BW, Brown SP. Variation in pneumococcal
invasiveness metrics is driven by serotype carriage duration and initial risk of disease.
Epidemics. 2023;45:100731.
37. Meiring S, Cohen C, Quan V, de Gouveia L, Feldman C, Karstaedt A, et al. HIV
Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African
Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine
(PCV). PloS one. 2016;11(2):e0149104.
38. Rohr JK, Manne-Goehler J, Gómez-Olivé FX, Kahn K, Bärnighausen TW. The HIV Care
Cascade for Older Adults in Rural South Africa: A Longitudinal Cohort Study (2014-2019).
Journal of acquired immune deficiency syndromes (1999). 2024;96(4):334-40.
39. Lippman SA, El Ayadi AM, Grignon JS, Puren A, Liegler T, Venter WDF, et al.
Improvements in the South African HIV care cascade: findings on 90-90-90 targets from

successive population-representative surveys in North West Province. J Int AIDS Soc.
2019;22(6):e25295.
40.   Domenech de Cellès M, Arduin H, Lévy-Bruhl D, Georges S, Souty C, Guillemot D, et
al. Unraveling the seasonal epidemiology of pneumococcus. Proceedings of the National
Academy of Sciences. 2019;116(5):1802.
41.   Chochua S, Metcalf B, Li Z, Walker H, Tran T, McGee L, et al. Invasive Serotype 35B
Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015–2016.
Emerging Infectious Disease journal. 2017;23(6):922.
610

Figure 1: PRISMA flow diagram for the systematic review of the literature

Figure 2. CCRs in UM/HIC compared to L/LMIC, by age group, post-PCV introduction

A) In children under-5 – i) PCV13 VTs, ii) Other serotypes

B) In children approximately 5-14 years of age – i) PCV13 VTs, ii) Other serotypes

c) in adults 15 years and above – i) PCV13 VTs, ii) Other serotypes

Figure 3. CCRs by HIV status using South African data only, complete-case analysis; A) among children under-5 years of age, B) among children 5-14 years of age, C) among children and adults 15 years and older.

[1] The percentage of IPD cases missing HIV status was high (55% in children under-5 years of age, 63% in 5-14 year olds, and 68% in 15 year olds and above); the results of the analysis after imputing HIV status for those missing are included in supplementary information.

Table 1. Data included in the analyses of CCRs by age group, country income group and PCV status

Age group	Income group[1]	PCV period	Total carriage isolates	Total carriage study sample size	Total IPD isolates	Total population under surveillance[2]
<5 years	L/LMIC	pre-PCV	5,341	7,138	417	765,288
		post-PCV	6,666	14,750	246	2,938,546
	UM/HIC	pre-PCV	1,902	2,264	2,771	6,710,831
		post-PCV	6,464	14,747	4,235	57,600,000
5-14 years	L/LMIC	pre-PCV	1,006	2,495	66	490139
		post-PCV	1,727	4,649	59	1,675,842
	UM/HIC	pre-PCV	465	927	702	9,175,174
		post-PCV	56	291	501	13,500,000
15 years and above	L/LMIC	pre-PCV	504	3,575	38	769,775
		post-PCV	1,099	6,076	133	3,116,886
	UM/HIC	pre-PCV	375	243	7,564	13,000,000
		post-PCV	29	807	24,506	53,400,000
Total			25,634	5,7962	41,238	16,3142,481

Abbreviations: IPD: Invasive pneumococcal disease; L/LMIC: Low and lower-middle income countries; PCV: Pneumococcal conjugate vaccine; UM/HIC: Upper-middle and high-income countries.

[1]This excludes South African data as it was inappropriate to combine South African data with other UM/HICs with much lower HIV prevalences due to the heterogeneity introduced in summary CCR estimates.

[2]If surveillance population sizes were not provided in the publication or by authors, but IPD surveillance was reportedly conducted nationwide, the population size was estimated from the most relevant census (i.e., for Belgium, Brazil, Burkina Faso, Cuba, Denmark, France, Iceland, Norway). If the surveillance population size was provided but was not disaggregated by age group or calendar year, it was divided by the proportion of the population in each age group from the most recent national census, and equally across the calendar years (i.e., Malawi, The Gambia).

Table 2. Vaccine-type (VT) and non-vaccine type (NVT) CCRs by PCV introduction status, country income group and age group

Serotype-groups	Pre-PCV				Post-PCV			
	L/LMIC		UM/HIC excl. SA		L/LMIC		UM/HIC excl. SA	
	CCR	95%CI	CCR	95%CI	CCR	95%CI	CCR	95%CI
Children <5 yrs of age								
NVT	152.2	102.6 - 225.8	102.1	49.9 - 208.9	154.0	118.9 - 199.5	18.7	16.2 - 21.5
PCV7 types	152.1	112.9 - 204.8	80.3	60.3 - 107.0	100.8	74.9 - 135.8	45.9	31.7 - 66.5
PCV10 additional types	2891.3	1990.1 - 4200.6	984.2	364.5 - 2657.4	1261.4	759.1 - 2096.2	114.6	62.4 - 210.4
PCV13 additional types	112.2	91.5 - 137.6	42.2	22.4 - 79.4	85.6	38.7 -189.6	72.5	53.4 - 98.4
PCV15 additional types	-	-	158.5	58.2 - 432.1	-	-	104.7	69.2 - 158.3
PCV20 additional types	323.1	146.0 - 714.7	45.0	11.0 -184.3	238.3	156.1 -363.6	30.0	20.2 - 44.5
5-14 yrs of age								
NVT	80.2	11.9 - 541.1	2.7	0.9 - 8.2	85.5	35.3 - 207.1	9.5	6.5 -14.0
PCV7 types	77.9	25.9 - 234.0	13.0	8.8 -19.1	85.9	34.8 - 211.9	21.9	9.2 -51.8
PCV10 additional types	1668.3	818.0 - 3402.5	62.6	24.8 - 158.1	243.3	137.2 - 431.6	66.2	17.6 -249.2
PCV13 additional types	55.2	26.1 - 116.7	4.6	3.0 - 7.0	43.3	5.0 - 373.3	22.9	9.6 -54.9
PCV15 additional types	-	-	34.8	0.3 - 4140.6	-	-	43.3	13.0 -145.1
PCV20 additional types	1278.2	26.9 - 61000	3.7	1.4 - 9.9	97.5	30.9 - 307.3	8.0	3.8 -16.8
15 years and above								
NVT	395.6	156.9 - 997.3	46.1	18.8 - 113.0	70.8	45.4 - 110.6	153.8	110.2 -214.6
PCV7 types	357.8	125.1 - 1023.3	311.8	125.6 - 774.1	64.9	36.9 - 114.2	183.6	97.1 -347.0
PCV10 additional types	1818.1	550.6 - 6003.8	491.8	144.1 - 1678.2	379.7	198.1 - 728.0	1923.2	150.4 -25000.0
PCV13 additional types	73.8	31.3 - 174.1	303.6	131.4 - 701.5	35.2	23.2 - 53.4	715.8	311.9 -1642.7
PCV15 additional types	-	-	317.2	40.2 - 2503.1	-	-	973.3	368.3 -2572.0
PCV20 additional types	-	-	213.8	60.3 - 757.9	129.0	45.9 - 362.5	229.7	115.6 -456.3

Serotype groups are exclusive i.e. NVT are non-PCV20 serotypes. Point estimates are not displayed if 95%CI could not be computed due to data sparsity.
Abbreviations: CCR: case-carrier ratio interpreted as e.g. IPD incidence of 152 cases per 100,000 population, per carrier detected in a cross-sectional carriage survey. L/LMIC: low and lower-middle income countries; PCV: pneumococcal conjugate vaccine; UM/HIC: upper-middle and high-income countries.